Aarti Pharmalabs Announces FY2026 Results, Recommends Dividend, and Approves Management Appointments
Aarti Pharmalabs Limited (Aarti Pharmalabs) announced key corporate decisions following its Board of Directors meeting held on May 25, 2026. The board approved the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026, and recommended a final dividend for the period.The company also finalized re-appointments for its statutory and internal auditors and designated senior management personnel.
Financial Results for FY2026
The company released its audited standalone and consolidated financial results for the period ending March 31, 2026.The consolidated results show total income of Rs. 182,918.89 lakhs for the year, compared to Rs. 212,350.04 lakhs for the year ended March 31, 2025.
The audited standalone financial statements summarize the operational performance:
| Particulars | FY Ended 31 March, 2026 | FY Ended 31 March, 2025 |
|---|---|---|
| Total Income | 59,023.06 lakhs | 52,958.57 lakhs |
| Total Expenses | 50,764.53 lakhs | 41,608.37 lakhs |
| Net Profit/(loss) for the period | 6,203.07 lakhs | 8,884.52 lakhs |
| Total Comprehensive Income for the period | 5,851.20 lakhs | 8,696.67 lakhs |
Aarti Pharmalabs also provided a detailed breakdown of its cash flow activities, showing:
| Metric | FY Ended 31 March, 2026 (Rs. lakhs) | FY Ended 31 March, 2025 (Rs. lakhs) |
|---|---|---|
| Net Cash Flow from Operating Activities | 25,725.77 | 33,858.06 |
| Net Cash Flow from Investing Activities | (42,514.02) | (41,837.65) |
| Net Cash Flow from Financing Activities | 17,058.42 | 7,863.48 |
| Closing Balance of Cash and Cash Equivalents | 553.68 | 399.62 |
Dividend Recommendation
The board recommended a Final Dividend of Rs. 2/- (Rupees Two only) per Equity Share. This dividend is based on a Face Value of Rs. 5/each for the Financial Year ended March 31, 2026, and is subject to the approval of the shareholders at the ensuing Annual General Meeting.Appointments and Governance
The board utilized its meeting on May 25, 2026, to re-appoint key internal and cost auditors and to designate senior management personnel.Auditor Re-appointments:
- Cost Auditor: Smt. Ketki D. Visariya, Cost Accountant (Membership No. 16028), was re-appointed as the Cost Auditor for the Financial Year 2026-27.
- Internal Auditor: Manish Modi & Associates, Chartered Accountant (Firm Registration No. 120780W), was re-appointed as the Internal Auditor for the Financial Year 2026-27.
Senior Management Personnel:
Effective May 25, 2026, Mr. Sachin Patil was designated as Head Exports, and Mr. Rajendra Pagare was designated as Head Operations & Compliance, both serving as Senior Management Personnel.
Balance Sheet Overview
The Balance Sheet provides a comparison of the company’s assets and liabilities structure.Standalone Balance Sheet (Amount Rs. in lakhs)
| Particulars | 31st March, 2026 | 31st March, 2025 |
|---|---|---|
| Total Assets | 332,776.47 | 271,963.15 |
| Non-Current Assets | 193,433.28 | 151,080.72 |
| Current Assets | 139,343.21 | 120,882.43 |
| Total Equity and Liabilities | 332,776.47 | 271,963.15 |
The consolidated financial results reflect the results from the Parent Company and its subsidiaries, including Aarti USA Inc., Aarti Pharmachem Limited, and the joint venture Ganesh Polychem Limited.
Standalone Balance Sheet Details
On the balance sheet as at March 31, 2026, Property, Plant and Equipment stood at 133,591.82 lakhs, an increase from 101,346.46 lakhs in the previous year. The total current assets amounted to 139,343.21 lakhs, compared to 120,882.43 lakhs in the previous year.
AARTIPHARM Stock Price Movement
On Monday, Aarti Pharmalabs Limited shares rallied, closing at ₹732.45, up 2.66% for the day. The equity saw notable trading activity, logging a total volume of 160,880 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: